Literature DB >> 35186160

F-18 FDG PET/CT in NK/T-Cell Lymphoma that Progressed from Epstein-Barr Virus-Associated Hemophagocytic Lymphohistiocytosis.

Il-Hyun Kim1, Young-Sil An1, Su Jin Lee1, Joon-Kee Yoon1.   

Abstract

Hemophagocytic lymphohistiocytosis (HLH) is a syndrome involving an uncontrolled immune response with variable triggers. HLH is rare but highly fatal, even with proper treatment; therefore, early recognition and diagnosis are crucial for management. Although the role of F-18 fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) in HLH is poorly defined, it can provide valuable information on disease status and possible triggers. Herein, we report an F-18 FDG PET/CT study on a case of NK/T-cell lymphoma that progressed from Epstein-Barr virus-associated HLH. © Korean Society of Nuclear Medicine 2021.

Entities:  

Keywords:  Epstein-Barr virus; F-18 FDG PET/CT; Hemophagocytic lymphohistiocytosis; NK/T-cell lymphoma

Year:  2021        PMID： 35186160      PMCID： PMC8828808          DOI： 10.1007/s13139-021-00725-3

Source DB:  PubMed          Journal:  Nucl Med Mol Imaging        ISSN： 1869-3474


  10 in total

1.  HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis.

Authors:  Jan-Inge Henter; Annacarin Horne; Maurizio Aricó; R Maarten Egeler; Alexandra H Filipovich; Shinsaku Imashuku; Stephan Ladisch; Ken McClain; David Webb; Jacek Winiarski; Gritta Janka
Journal:  Pediatr Blood Cancer       Date:  2007-02       Impact factor: 3.167

2.  18F-FDG PET/CT for identifying the potential causes and extent of secondary hemophagocytic lymphohistiocytosis.

Authors:  Leilei Yuan; Ying Kan; Jacqui K Meeks; Daqing Ma; Jigang Yang
Journal:  Diagn Interv Radiol       Date:  2016 Sep-Oct       Impact factor: 2.630

Review 3.  Adult haemophagocytic syndrome.

Authors:  Manuel Ramos-Casals; Pilar Brito-Zerón; Armando López-Guillermo; Munther A Khamashta; Xavier Bosch
Journal:  Lancet       Date:  2013-11-27       Impact factor: 79.321

4.  Longitudinal observation and outcome of nonfamilial childhood haemophagocytic syndrome receiving etoposide-containing regimens.

Authors:  J S Chen; K H Lin; D T Lin; R L Chen; S T Jou; I J Su
Journal:  Br J Haematol       Date:  1998-12       Impact factor: 6.998

Review 5.  Positron emission tomography as a diagnostic tool in infection: present role and future possibilities.

Authors:  Sandip Basu; Timothy Chryssikos; Siamak Moghadam-Kia; Hongming Zhuang; Drew A Torigian; Abass Alavi
Journal:  Semin Nucl Med       Date:  2009-01       Impact factor: 4.446

6.  Clinical implication of F-18 FDG PET/CT in patients with secondary hemophagocytic lymphohistiocytosis.

Authors:  Jahae Kim; Su Woong Yoo; Sae-Ryung Kang; Hee-Seung Bom; Ho-Chun Song; Jung-Joon Min
Journal:  Ann Hematol       Date:  2013-09-24       Impact factor: 3.673

Review 7.  Pathogenesis and mechanism of disease progression from hemophagocytic lymphohistiocytosis to Epstein-Barr virus-associated T-cell lymphoma: nuclear factor-kappa B pathway as a potential therapeutic target.

Authors:  Huai-Chia Chuang; Jong-Ding Lay; Wen-Chuan Hsieh; Ih-Jen Su
Journal:  Cancer Sci       Date:  2007-07-11       Impact factor: 6.716

8.  The role of 18F-FDG PET/CT in the management of patients with secondary haemophagocytic lymphohistiocytosis.

Authors:  Y Zheng; G Hu; Y Liu; Y Ma; Y Dang; F Li; H Xing; T Wang; L Huo
Journal:  Clin Radiol       Date:  2016-07-04       Impact factor: 2.350

Review 9.  Challenges in the diagnosis of hemophagocytic lymphohistiocytosis: Recommendations from the North American Consortium for Histiocytosis (NACHO).

Authors:  Michael B Jordan; Carl E Allen; Jay Greenberg; Michael Henry; Michelle L Hermiston; Ashish Kumar; Melissa Hines; Olive Eckstein; Stephan Ladisch; Kim E Nichols; Carlos Rodriguez-Galindo; Birte Wistinghausen; Kenneth L McClain
Journal:  Pediatr Blood Cancer       Date:  2019-07-24       Impact factor: 3.167

10.  The significance of pre-therapeutic F-18-FDG PET-CT in lymphoma-associated hemophagocytic lymphohistiocytosis when pathological evidence is unavailable.

Authors:  Jujuan Wang; Dongjiao Wang; Qingbo Zhang; Limin Duan; Tian Tian; Xiaoyan Zhang; Jianyong Li; Hongxia Qiu
Journal:  J Cancer Res Clin Oncol       Date:  2015-12-15       Impact factor: 4.553
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.